Journal article
"Eye-Black" Sign Secondary to Nivolumab Immunotherapy
Clinical nuclear medicine, Vol.45(3), pp.217-219
03/01/2020
DOI: 10.1097/RLU.0000000000002846
PMID: 31876808
Abstract
A 54-year-old woman with known chest wall melanoma (post-wide local excision) presented for imaging after a yearlong therapy with nivolumab. F-18-FDG PET/CT was performed 1 day after she completed the immunotherapy. Maximum intensity projection images showed bilateral relatively symmetrical uptake in the facial region. On fused PET/CT images, the uptake was seen corresponding to subcutaneous malar prominence underneath the orbits (like eye-black stripe used in sports) with subcutaneous malar calcification. Repeat PET/CT performed after 3 months revealed significant decrease in the malar uptake. Interval resolution of the uptake likely suggested this being inflammatory and secondary to immunotherapy.
Details
- Title: Subtitle
- "Eye-Black" Sign Secondary to Nivolumab Immunotherapy
- Creators
- Sarv Priya - University of Iowa Hospitals and ClinicsMichael Graham - Univ Iowa Hosp, Div Nucl Med, Dept Radiol, 200 Hawkins Dr, Iowa City, IA 52242 USA
- Resource Type
- Journal article
- Publication Details
- Clinical nuclear medicine, Vol.45(3), pp.217-219
- Publisher
- Lippincott Williams & Wilkins
- DOI
- 10.1097/RLU.0000000000002846
- PMID
- 31876808
- ISSN
- 0363-9762
- eISSN
- 1536-0229
- Number of pages
- 3
- Language
- English
- Date published
- 03/01/2020
- Academic Unit
- Radiology; Radiation Oncology
- Record Identifier
- 9984312977202771
Metrics
4 Record Views